Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


3i and SEB Företagsinvest divest stakes in SBL Vaccines in sale to Crucell


21 November 2006 - 3i, world leading venture capital and private equity company, SEB Företagsinvest, a leading Nordic venture capitalist and other shareholders are divesting their stakes in SBL Vaccines, leading vaccine distributor in Sweden, in a sale to NASDAQ listed Dutch biotechnology company Crucell (CRXL). The sale price is €39.4 million, excluding deferred payments and future royalties. It is expected that the transaction will be completed on November 23, 2006.

SBL Vaccines is a Swedish company, specialising in the development, manufacture and marketing of vaccines and niche pharmaceuticals. SBL Vaccines’ core product Dukoral® is an orally administered drug that protects against cholera and ETEC, causing what is commonly known as travellers’ diarrhoea. Dukoral® is licensed and available in more than 50 countries worldwide. Sales exceeded €14.7m in 2005, representing a dramatic increase of over 60% since 2004. Apart from Dukoral® SBL Vaccines markets and sells vaccines, produced by big international companies, in the Nordic market. The company’s total turnover 2005 was €38 million.

Thomas Pollare, Partner, 3i Nordic, said:”We’re proud to have worked together with CEO Björn Sjöstrand, EVP Mats Lidgard and other management to help transform SBL Vaccines from a loss-making company to the successful profitable business it is today. Showing progress well ahead of plan, now is the right time for SBL Vaccines to further grow its Dukoral business under the leadership of Crucell, a strong international and marketing organisation and an excellent fit for SBL Vaccines’ strategy going forward.”

Björn Sjöstrand, Managing Director, SBL Vaccines, commented:” Behind SBL Vaccine’s transformation is not only the extensive restructuring of the business but above all strong growth in sales of Dukoral, the oral travel vaccine. Through the merger with Crucell, the company achieves great potential for further growth. We are very happy of the support we have got from 3i and SEB Företagsinvest, in the form of experience and capital. This has helped us to become a profitable and forward looking company.”

Jonas Nyman, Senior Investment Manager, SEB Företagsinvest, said: ”SBL Vaccines is today a leading Nordic vaccines company and a strong brand in the vaccine industry. Through Crucell, SBL gets access to Crucell’s global sales and marketing organisation, which means improved opportunities for SBL Vaccines to market Dukoral® outside of the Nordic region.


For further information, please contact:
Rachel Richards, Press Officer, 3i Press Office: Tel. +44 207 975 3573; Mobile +44 7808 947122

Thomas Pollare, Partner, 3i Nordic plc (UK), advisor to 3i Group plc: Tel. +46 8 506 101 65, Mobile +46 708 10 79 29

Jonas Nyman, Senior Investment Manager, SEB Företagsinvest: Tel. +46 8 763 79 05, Mobile +46 702 65 79 05

Björn Sjöstrand, Managing Director, SBL Vaccin: Tel. +46 735 14 40, +46 709 10 58 09


About 3i Group
3i is a world leader in private equity and venture capital. We focus on Buyouts, Growth Capital and Venture Capital and invest across Europe, in the United States and in Asia. Our competitive advantage comes from our international network and the strength and breadth of our relationships in business. These underpin the value that we deliver to our portfolio and to our shareholders. www.3i.com


About SEB Företagsinvest
SEB Företagsinvest is the venture capital arm of SEB. SEB Företagsinvest invests venture capital and adds competence to and provides a network for companies with substantial growth potential. The focus is on Technology and Life Science. www.seb.se/foretagsinvest


About SBL Vaccines
SBL Vaccines is a privately owned Swedish company, specialising in the development, manufacture and marketing of vaccines and niche pharmaceuticals. The primary research focus is the field of diarrhoeal diseases.

In the Nordic region, SBL Vaccines markets a complete vaccine portfolio sourced<


Publisher Contact Information:

3i Group plc
+44 (0)20 7975 3573
rachel.richards@3i.com

Company profile of 3i Group plc
Past press releases of 3i Group plc .

Data


27,730
Tech investments
From our Online Data Service
17,884
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.